HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer

• ClinicalTrials.gov Identifier: NCT04403620
• Recruitment Status: Recruiting
• First Posted: May 27, 2020
• Last Update Posted: March 2, 2023
• Sponsor: University of Texas Southwestern Medical Center
• Information provided by (Responsible Party): Dominic Moon, University of Texas Southwestern Medical Center

Study Description

Brief Summary:

There is a strong radiobiological and economic rationale for hypofractionated radiation therapy in head and neck cancer. Phase 1 of the trial aims to assess the acute toxicity and tolerability of hypofractionated radiation therapy in the post-operative setting, and to determine the dose/fractionation for Phase 2. Phase 2 aims to establish non-inferiority of swallowing-related quality of life and to assess the toxicity and efficacy of hypofractionated radiation therapy compared to conventionally fractionated radiation therapy in the post-operative setting.

Condition or disease	Intervention/treatment	Phase
Squamous Cell Carcinoma of Head and Neck	Radiation: Intensity-modulated Radiation Therapy (IMRT)	Phase 1; Phase 2

Detailed Description:

The trial will assess the effects of aggressive hypofractionated radiation therapy in patients with oral cavity, oropharynx, hypopharynx, or larynx cancer after surgical resection with pathology showing intermediate risk factors requiring post-operative radiation therapy without concurrent chemotherapy. During Phase 1, the maximum tolerated dose/fractionation and tolerability will be determined. During Phase 2, patients will be randomized between conventionally fractionated radiation therapy (6 weeks) vs. hypofractionated radiation therapy (3 weeks) to establish non-inferiority of hypofractionated radiation therapy.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 98 participants
• Allocation: Randomized
• Intervention Model: Sequential Assignment
• Intervention Model Description: Dose/fractionation finding Phase 1 study, followed by a randomized Phase 2 study
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Squamous Cell Carcinoma
• Actual Study Start Date: July 28, 2020
• Estimated Primary Completion Date: August 2027
• Estimated Study Completion Date: August 2027

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Conventionally fractionated radiotherapy; 60 Gy in 30 fractions, 5 fractions/week	Radiation: Intensity-modulated Radiation Therapy (IMRT); Patients will receive adjuvant radiation therapy using intensity-modulated radiation therapy (IMRT) within 8 weeks of surgical resection
Experimental: Hypofractionated radiotherapy; Dose and fractionation determined by Phase I: Level 1: 44.4 Gy in 12 fractions, 4 fractions/week Level 0: 46.5 Gy in 15 fractions, 5 fractions/week Level -1: 52 Gy in 20 fractions, 5 fractions/week Level -2: 50 Gy in 20 fractions, 5 fractions/week	Radiation: Intensity-modulated Radiation Therapy (IMRT); Patients will receive adjuvant radiation therapy using intensity-modulated radiation therapy (IMRT) within 8 weeks of surgical resection

Outcome Measures

Primary Outcome Measures :

1. Phase 1: Maximally tolerated dose of hypofractionated radiation therapy [ Time Frame: 3 months ]
   Dose and fractionation to be used for Phase 2
2. Phase 2: Swallowing-related patient-reported quality of life [ Time Frame: 12 months ]
   MD Anderson Dysphagia Inventory (MDADI) composite score: 20-100, higher scores mean better quality of life

Secondary Outcome Measures :

1. Clinician-reported acute toxicities [ Time Frame: 1-3 months ]
   CTCAE v5.0
2. Clinician-reported late toxicities [ Time Frame: 6-24 months ]
   CTCAE v5.0
3. Locoregional control [ Time Frame: 12-24 months ]
4. Progression free survival [ Time Frame: 12-24 months ]
5. Swallowing-related patient-reported quality of life [ Time Frame: 1-24 months ]
   MD Anderson Dysphagia Inventory (MDADI): 20-100, higher scores mean better quality of life
6. Head and neck patient-reported quality of life [ Time Frame: 1-24 months ]
   University of Washington QOL questionnaire (UW-QOL): 0-100, higher scores mean better quality of life
7. Xerostomia-related patient-reported quality of life [ Time Frame: 1-24 months ]
   University of Michigan Xerostomia questionnaire (XQ): 0-100, higher scores mean worse quality of life
8. General patient-reported quality of life [ Time Frame: 1-24 months ]
   EuroQol-5 dimensions (EQ-5D-5L): 1-5, higher scores mean worse quality of life
9. Feeding tube dependence [ Time Frame: 1-24 months ]
   Feeding tube dependence defined as daily use of the feeding tube with ≥2 nutritional supplements (e.g. Ensure, Boost, etc.) per day at the time of enrollment on trial

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Inclusion criteria will be the same for Phase I and Phase II.

1. Pathologically proven diagnosis of stage I-IVB squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx status post gross total resection with pathology showing one or more of the following intermediate risk factors:

   • T3/4 disease (AJCC 8th edition), positive lymph node(s), close margin(s), perineural invasion, and/or lymphovascular invasion

   • Close margin(s) defined as either:

     • Final patient margin of <5 mm without disease on ink OR
     • Initial positive margin in the specimen regardless of the final patient margin (e.g. if resection margin on the initial specimen is positive, final patient margin after subsequent resections can be ≥5 mm and still be considered close margin)
2. Age ≥18 years
3. ECOG performance status 0-2

4. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy.

   Medically acceptable birth control (contraceptives) includes:

   • approved hormonal contraceptives (such as birth control pills, patch or ring; Depo-Provera, Implanon), or
   • barrier methods (such as condom or diaphragm) used with a spermicide

   Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

   A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

   • Has not undergone a hysterectomy or bilateral oophorectomy; or
   • Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
5. Negative serum or urine pregnancy test within 2 weeks before registration for women of childbearing potential.
6. Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

Phase I:

1. Distant metastasis
2. Stage I and II glottic squamous cell carcinoma
3. High risk factors following surgical resection requiring concurrent chemotherapy: final positive margin(s) and/or extranodal extension
4. Feeding tube dependence at baseline assessment.
5. Synchronous non-skin cancer primaries outside of the oropharynx, oral cavity, larynx, and hypopharynx except for low- and intermediate-risk prostate cancer and synchronous well-differentiated thyroid cancer. For prostate cancer, patient should not be receiving active treatment. For thyroid cancer, thyroid surgery may occur before or after treatment, provided all other eligibility criteria are met.
6. Prior invasive malignancy with an expected disease-free interval of less than 3 years
7. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation fields
8. Subjects may not be receiving any other investigational agents for the treatment of the cancer under study.
9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements
10. Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
11. History of severe immunosuppression, including HIV, and organ or autologous or allogeneic stem cell transplant

Phase II:

The exclusion criteria will be the same as Phase I except for feeding tube dependence. Patients who are feeding tube dependent are excluded from Phase I to accurately assess treatment associated toxicity affecting swallowing and oral intake. During Phase II, patients who are feeding tube dependent will be eligible to enroll and stratified at randomization.

Contacts and Locations

Contacts

Contact: Sarah Neufeld, MS; 214-645-8525; sarah.hardee@utsouthwestern.edu

Contact: Kajal Desai, MS; kajal.desai@utsouthwestern.edu

Locations

United States, Texas

University of Texas Southwestern Medical Center; Recruiting

Dallas, Texas, United States, 75390

Sponsors and Collaborators

University of Texas Southwestern Medical Center

Investigators

• Principal Investigator: Dominic Moon, MD; UT Southwestern Medical Center

More Information

• Responsible Party: Dominic Moon, Assistant Professor, University of Texas Southwestern Medical Center
• ClinicalTrials.gov Identifier: NCT04403620
• Other Study ID Numbers: STU 2020-0522
• First Posted: May 27, 2020
• Last Update Posted: March 2, 2023
• Last Verified: March 2023

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Dominic Moon, University of Texas Southwestern Medical Center:

Radiation Dose Hypofractionation; Adjuvant Radiotherapy

Additional relevant MeSH terms:

Carcinoma; Carcinoma, Squamous Cell; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Squamous Cell; Head and Neck Neoplasms; Neoplasms by Site